Drugs / XT-150
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06704347 | Nov 2025 → Mar 2027 expected | amyotrophic lateral sclerosis | Xalud Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04466410 | Apr 2021 → Sep 2022 | neuropathy, painful | Xalud Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03769662 | Mar → Oct 2019 | osteoarthritis, knee | Xalud Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03477487 | Jun 2018 → Jul 2019 | osteoarthritis, knee | Xalud Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03282149 | Mar 2018 → Mar 2019 | osteoarthritis, knee | Xalud Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04841512 | Oct 2021 → Mar 2022 | osteoarthritis, spine | Xalud Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT05196919 | Feb 2022 → Sep 2023 | — | Xalud Therapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT04124042 | Feb 2020 → Apr 2022 | osteoarthritis, knee | Xalud Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XT-150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05196919 ↗ |
| Modality | Other / unclassified | “a DNA plasmid with a variant Interleukin-10 (IL-10) transgene” NCT03282149 ↗ |
| Route | Other | “injected into the synovial capsule of the knee” NCT03282149 ↗ |